NCT04993690View on ClinicalTrials.gov

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
B-cell Lymphoma
Interventions
DRUG

LP-168 tablet

Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily

Trial Locations (3)

100089

RECRUITING

Peking University Third Hospital, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY